Pantoprazole Sodium Price Trends
The price of pantoprazole sodium has seen a downward trend in recent years, largely due to the availability of generic versions. Originally marketed under the brand name Protonix, pantoprazole is a proton pump inhibitor (PPI) used to treat conditions like gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome.
When did generic pantoprazole become available?
Generic versions of pantoprazole sodium began entering the market after the expiration of key patents. For instance, the compound patent for pantoprazole sodium expired around 2007-2008 in the United States, paving the way for generic manufacturers to produce and sell their own versions of the drug [1].
How has patent expiration affected pantoprazole prices?
The introduction of multiple generic pantoprazole sodium products significantly increased market competition. This competition, a common outcome following patent expiry for branded drugs, generally leads to lower prices for consumers and healthcare systems as manufacturers vie for market share [2].
What are the current price ranges for generic pantoprazole sodium?
Current pricing for generic pantoprazole sodium varies depending on the dosage, form (tablets, capsules, or injection), and the specific manufacturer or pharmacy. However, prices are considerably lower than when the drug was exclusively available as a branded product. For example, a supply of 30 pantoprazole sodium 40 mg tablets can often be found for under $10 USD at many retail pharmacies, with even lower prices available through online discount providers or wholesale purchasing [3].
Who are the main manufacturers of generic pantoprazole sodium?
Numerous pharmaceutical companies manufacture generic pantoprazole sodium. Major players in the generic drug market, such as Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and Aurobindo Pharma, are among the producers of pantoprazole sodium [4].
Are there any ongoing patent disputes or exclusivity issues for pantoprazole sodium?
While the primary patents covering the pantoprazole molecule have expired, there may still be secondary patents related to specific formulations, methods of manufacturing, or extended-release versions. However, these typically do not prevent the broad availability of generic pantoprazole sodium [1]. Information on specific patent statuses and litigation can be found on DrugPatentWatch.com [1].
How does pantoprazole sodium's price compare to other PPIs?
Pantoprazole sodium is generally one of the more affordable generic proton pump inhibitors. Its price is often comparable to or lower than other widely available generic PPIs such as omeprazole, lansoprazole, and esomeprazole, especially when purchased in generic form [3].
What are the typical dosages and forms of pantoprazole sodium available?
Pantoprazole sodium is commonly available in oral forms, including delayed-release tablets and capsules, typically in strengths of 20 mg and 40 mg. It is also available as a powder for injection, used in hospital settings for patients who cannot take oral medication [5].
What are the potential side effects of pantoprazole sodium that patients should be aware of?
Common side effects associated with pantoprazole sodium include headache, diarrhea, nausea, and abdominal pain. Long-term use of PPIs like pantoprazole has also been associated with potential risks such as bone fractures, vitamin B12 deficiency, and kidney problems, though these are generally rare [6].
Where can I find more detailed patent information and expiration dates for pantoprazole sodium?
Detailed information regarding pantoprazole sodium's patent status, including expiration dates and potential for new market entrants, can be accessed through specialized pharmaceutical patent databases like DrugPatentWatch.com [1].
Sources:
[1] DrugPatentWatch.com
[2] (General knowledge of pharmaceutical market dynamics post-patent expiry)
[3] (Based on current retail pricing data from major US pharmacies and online retailers)
[4] (Based on market presence of major generic pharmaceutical manufacturers)
[5] National Institutes of Health. (2022). Pantoprazole. MedlinePlus.
[6] U.S. Food and Drug Administration. (n.d.). Proton Pump Inhibitors.